Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
letter
. 2020 Jul 15;144:110109. doi: 10.1016/j.mehy.2020.110109

BCG vaccination and COVID-19: Much ado about nothing?

M Caminati a,, F Furci b, G Senna a, G Delfino c, A Poli d, C Bovo e, V Patella c,f
PMCID: PMC7361052  PMID: 32758899

We read with great interest the article “Relation between BCG coverage rate and COVID-19 infection worldwide” by Macedo et al. [1], which provides a worldwide overview of vaccination programmes and COVID-19 burden in different countries, and postulates that BCG may protect from COVID-19.

By relying on speculation more than on evidence the current scientific debate seems to value the idea of a BCG-related lower susceptibility to COVID-19 [2]. As a proof of concept, different authors reported a limited COVID-19 burden in BCG vaccinated countries [2], [3], [4], [5]. The hypothesis is certainly supported by a strong immunological rationale. In fact, BCG vaccination may contribute to polarize the physiological immune reaction toward a Th1 pattern and exert an additional protective role against viruses [6].

However, when looking at the different distribution of COVID-19 outbreak worldwide according to BCG coverage, several confounding factors should be considered.

The low temperature facilitates the virus spread. The most affected countries experienced the COVID-19 pandemic during their wintertime [7], which could explain the difference between the northern and southern hemisphere besides BCG vaccination.

Furthermore, depending on the local health care system, case identification resources, including COVID-19 swabs, may vary in different countries, which is relevant when sizing the impact of a viral infection.

In Europe, where the above-mentioned variables are quite homogeneous, COVID-19 outbreak is still lower where BCG vaccination is regularly provided [8]. It is the case of Eastern Countries (except Portugal). However, the population mean age in BCG unvaccinated states is significantly higher in comparison to vaccinated ones (respectively 40.9-SD 3.1- vs 37.8-SD 5.7- years; t-test: p = 0.031), as well as the mean life expectancy (respectively 81.6-SD 1.7 vs 75.0-SD 2.6 years; t-test: p < 0,001) [8]. This evidence is not negligible when considering that most of COVID-19 fatal cases were registered in patients older than 70.

Furthermore, the population’s density is significantly higher in BCG unvaccinated countries (median 127.6 [IQR: 83,1 – 230.5] inhabitants/Km2 vs 73.7 [IQR: 45.0 –101.0]; Mann- Whitney test: p = 0.003). The difference is remarkable when considering its relevance in facilitating the infection from human to human [9]. The same effect can be exerted by the international commercial exchanges and air traffic, which is much more relevant in European Western Countries, primarily interested by the COVID-19 outbreak.

In the light of the above-mentioned determinants, the hypothetic relevance of BCG-vaccination as a protection from COVID-19, although fascinating, remains quite controversial and further focused research is required besides speculation.

Acknowledgments

Acknowledgements

Not applicable.

Conflict of interest statement

The authors declare no conflicts of interest.

Funding

No funding to declare.

References

  • 1.Macedo A., Febra C. Relation between BCG coverage rate and COVID-19 infection worldwide. Med Hypotheses. 2020;142:109816. doi: 10.1016/j.mehy.2020.109816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Curtis N., Sparrow A., Ghebreyesus T.A., Netea M.G. Considering BCG vaccination to reduce the impact of COVID-19. Lancet. 2020;395:1545–1546. doi: 10.1016/S0140-6736(20)31025-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study, medRxiv, DOI:10.1101/2020.03.24.20042937.
  • 4.Ozdemir C, Kucuksezer UC, Tamay ZU. Is BCG vaccination affecting the spread and severity of COVID-19? Allergy. 2020. Online ahead of print. [DOI] [PubMed]
  • 5.Sala G & Miyagawa T, Association of BCG vaccination policy with prevalence and mortality of COVID-19”, medRxiv, DOI:10.1101/2020.03.30.20048165.
  • 6.Netea M.G., Domínguez-Andrés J., Barreiro L.B. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020 doi: 10.1038/s41577-020-0285-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Wu Y.u., Jing W., Liu J., Ma Q., Yuan J., Wang Y., Du M., Liu M. Effects of temperature and humidity on the daily new cases and new deaths of COVID-19 in 166 countries. Sci Total Environ. 2020;729:139051. doi: 10.1016/j.scitotenv.2020.139051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.An official website of the European Union. https://ec.europa.eu/eurostat/web/products-eurostat-news. Accessed May 18 th, 2020.
  • 9.Chandra S., Kassens-Noor E., Kuljanin G., Vertalka J. Int A geographic analysis of population density thresholds in the influenza pandemic of 1918–19. J Health Geogr. 2013;20(12):9. doi: 10.1186/1476-072X-12-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Medical Hypotheses are provided here courtesy of Elsevier

RESOURCES